CDER Outlines its Drug Safety Priorities During the Pandemic

Like other parts of the FDA, the Center for Drug Evaluation and Research had to scramble last year to address COVID-19 while not losing sight of its other important tasks, according to its latest annual report on Drug Safety Priorities.
Source: Drug GMP Report